Literature DB >> 33581965

Magnolol ameliorates the accumulation of reactive oxidative stress and inflammation in diabetic periodontitis.

Chia-Ming Liu1, Szu-Han Chen2, Yi-Wen Liao3, Chuan-Hang Yu1, Cheng-Chia Yu4, Pei-Ling Hsieh5.   

Abstract

BACKGROUND/
PURPOSE: Periodontal disease and diabetes mellitus (DM) are both chronic inflammatory and highly prevalent diseases. A large amount of evidence suggested that the accumulation of oxidative stress plays a significant role in the deterioration of both diseases. Magnolol has been known to possess anti-inflammatory and anti-oxidant activities in various tissues, but its effects on gingival cells under diabetic conditions have not been fully understood.
METHODS: We assessed the generation of reactive oxygen species (ROS), Transwell migration, and wound healing ability in response to the advanced glycation end products (AGEs) stimulation with or without Magnolol treatment. Subsequently, we examined the expression of Nrf2 and HO-1 to ascertain whether Magnolol was able to activate the anti-oxidant signaling. We also measured the secretion of IL-6 and IL-8, and conducted a knockdown experiment to elucidate the effect of Mrf2 on their secretion.
RESULTS: The AGEs-induced ROS was dose-dependently downregulated following the Magnolol treatment. Likewise, the reduced Transwell migration and wound healing ability were improved by various concentrations of Magnolol. Results from qRT-PCR indicated that the suppression of Nrf2 and HO-1 following AGEs stimulation was reversed by Magnolol. Also, the AGEs-elicited production of IL-6 and IL-8 was inhibited by Magnolol. Moreover, our results demonstrated that this anti-inflammatory effect was mediated by the upregulation of Nrf2.
CONCLUSION: These findings showed that excessive AGEs in the gingiva may lead to the accumulation of ROS and pro-inflammatory cytokines. Supplement of Magnolol may be beneficial to improve the impaired wound healing and inflammation by upregulation of Nrf2 signaling for DM patients with periodontal disease.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Advanced glycation end products; Magnolol; Periodontitis

Mesh:

Substances:

Year:  2021        PMID: 33581965     DOI: 10.1016/j.jfma.2021.01.010

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  4 in total

1.  Magnolol upregulates CHRM1 to attenuate Amyloid-β-triggered neuronal injury through regulating the cAMP/PKA/CREB pathway.

Authors:  Gemin Zhu; Yuan Fang; Xiaoli Cui; Ruihua Jia; Xiaogang Kang; Rui Zhao
Journal:  J Nat Med       Date:  2021-10-27       Impact factor: 2.343

Review 2.  Pathogenic Molecular Mechanisms in Periodontitis and Peri-Implantitis: Role of Advanced Glycation End Products.

Authors:  Grigorios Plemmenos; Christina Piperi
Journal:  Life (Basel)       Date:  2022-01-30

Review 3.  Anti-Inflammatory and Antioxidant Properties of Carvacrol and Magnolol, in Periodontal Disease and Diabetes Mellitus.

Authors:  Georgiana Ioana Potra Cicalău; Petru Aurel Babes; Horia Calniceanu; Adelina Popa; Gabriela Ciavoi; Gilda Mihaela Iova; Mariana Ganea; Ioana Scrobotă
Journal:  Molecules       Date:  2021-11-16       Impact factor: 4.411

4.  PINK1 mediated mitophagy attenuates early apoptosis of gingival epithelial cells induced by high glucose.

Authors:  Chunhui Zhu; Ying Zhao; Dandan Pei; Zhongbo Liu; Jin Liu; Ye Li; Shuchen Yu; Lingyan Ma; Junyi Sun; Ang Li
Journal:  BMC Oral Health       Date:  2022-04-26       Impact factor: 3.747

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.